Erismodegib in basal cell nevus syndrome patients with basal cell carcinoma

Trial Profile

Erismodegib in basal cell nevus syndrome patients with basal cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2011

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Basal cell cancer; Basal cell nevus syndrome
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 12 Aug 2011 New trial record
    • 01 Aug 2011 Results published in the Journal of Investigative Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top